Cellectis (CLLS) Share-based Compensation Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -34.72% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 4.80% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 10.78% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.55% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.65% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 0.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.88% |
| Dec 31, 2025 | 79.81% |
| Sep 30, 2025 | -445.67% |
| Jun 30, 2025 | 21.33% |
| Mar 31, 2025 | -25.03% |
| Dec 31, 2024 | 957.53% |
| Sep 30, 2024 | -370.52% |
| Jun 30, 2024 | -494.41% |
| Mar 31, 2024 | 209.22% |
| Dec 31, 2023 | 54.14% |
| Sep 30, 2023 | 822.35% |
| Jun 30, 2023 | -608.67% |
| Mar 31, 2023 | -30.26% |
| Dec 31, 2022 | -62.07% |
| Sep 30, 2022 | 7.76% |
| Jun 30, 2022 | -44.05% |
| Mar 31, 2022 | -23.10% |
| Dec 31, 2021 | -37.85% |
| Sep 30, 2021 | -12.04% |
| Jun 30, 2021 | -23.76% |
| Mar 31, 2021 | -86.43% |
| Dec 31, 2020 | -30.89% |
| Sep 30, 2020 | -35.97% |
| Jun 30, 2020 | -45.07% |
| Mar 31, 2020 | -29.48% |
| Dec 31, 2019 | -20.45% |
| Sep 30, 2019 | -16.13% |
| Jun 30, 2019 | -25.50% |
| Mar 31, 2019 | -29.92% |
| Dec 31, 2018 | -16.50% |
| Sep 30, 2018 | -8.21% |
| Jun 30, 2018 | 4.32% |
| Mar 31, 2018 | 133.08% |